Format

Send to

Choose Destination
Cancer Immunol Res. 2018 Jan 23. doi: 10.1158/2326-6066.CIR-16-0358. [Epub ahead of print]

Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16+ Oral Tumors and Immunologic Control.

Author information

1
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
2
Department of Obstetrics and Gynecology, Tri-Service General Hospital, Taipei City, Taiwan.
3
Department of Obstetrics and Gynecology, Tri-Service General Hospital, Penghu Branch, Taiwan.
4
Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung. Taiwan.
5
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland. chung2@jhmi.edu wutc@jhmi.edu.
6
Departments of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
7
Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, Maryland.
8
Department of Obstetrics and Gynecology, Johns Hopkins University, Baltimore, Maryland.

Abstract

Human papillomavirus type 16 (HPV16) is the etiologic factor for cervical cancer and a subset of oropharyngeal cancers. Although several prophylactic HPV vaccines are available, no effective therapeutic strategies to control active HPV diseases exist. Tumor implantation models are traditionally used to study HPV-associated buccal tumors. However, they fail to address precancerous phases of disease progression and display tumor microenvironments distinct from those observed in patients. Previously, K14-E6/E7 transgenic mouse models have been used to generate spontaneous tumors. However, the rate of tumor formation is inconsistent, and the host often develops immune tolerance to the viral oncoproteins. We developed a preclinical, spontaneous, HPV16+ buccal tumor model using submucosal injection of oncogenic plasmids expressing HPV16-E6/E7, NRas G12V , luciferase, and sleeping beauty (SB) transposase, followed by electroporation in the buccal mucosa. We evaluated responses to immunization with a pNGVL4a-CRT/E7(detox) therapeutic HPV DNA vaccine and tumor cell migration to distant locations. Mice transfected with plasmids encoding HPV16-E6/E7, NRas G12V , luciferase, and SB transposase developed tumors within 3 weeks. We also found transient anti-CD3 administration is required to generate tumors in immunocompetent mice. Bioluminescence signals from luciferase correlated strongly with tumor growth, and tumors expressed HPV16-associated markers. We showed that pNGVL4a-CRT/E7(detox) administration resulted in antitumor immunity in tumor-bearing mice. Lastly, we demonstrated that the generated tumor could migrate to tumor-draining lymph nodes. Our model provides an efficient method to induce spontaneous HPV+ tumor formation, which can be used to identify effective therapeutic interventions, analyze tumor migration, and conduct tumor biology research. Cancer Immunol Res; 6(3); 1-15. ©2018 AACR.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center